Urinary tract infections (UTIs), including cystitis and pyelonephritis, affect a large proportion of the population and account for significant medical costs. In more than 80% of UTIs, uropathogenic Escherichia coli (UPEC) is the causative pathogen. The initial step in the pathogenesis of the infection is the adherence of UPEC to the human bladder epithelium, enabling the invasion into the host cells and the development of UTIs. This process is mediated by the lectin FimH located on type I pili and enables UPECs to attach to oligomannosides of the glycoprotein uroplakin Ia presented on uroepithelial cells. FimH antagonists such as α-d-mannopyranosides have been shown to interfere with the attachment of UPEC to their host cells, thus providing a novel therapeutic opportunity for the treatment and prevention of UTIs. In this article, we report a flow cytometry-based assay to evaluate the potential of FimH antagonists for the prevention of the infection of the human urinary bladder cell line 5637 by UPEC strain UTI89. The assay was optimized and validated, and the inhibitory potency of different α-d-mannopyranosides was determined. Finally, the IC50 values measured by the flow cytometry-based assay were compared with those reported for other assay formats.
Get full access to this article
View all access options for this article.
References
1.
FoxmanB, BarlowR, D'ArcyH, GillespieB, SobelJD. Urinary tract infection: self reported incidence and associated costs. Ann Epidemiol, 2000; 10:509–515.
2.
RonaldA. The etiology of urinary tract infection: traditional and emerging pathogens. Acad Med, 2002; 113:14S–19S.
3.
FoxmanB, BrownP. Epidemiology of urinary tract infections—transmission and risk factors, incidence, and costs. Infect Dis Clin North Am, 2003; 17:227–241.
4.
FoxmanB. Recurring urinary tract infection: incidence and risk factors. Am J Public Health, 1990; 80:331–333.
5.
MulveyMA. Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol, 2002; 4:257–271.
6.
WilesTJ, KulesusRR, MulveyMA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Clin Mol Pathol, 2008; 85:11–19.
7.
RussellPW, OrndorffPE. Lesions in two Escherichia coli type 1 pilus genes alter pilus number and length without affecting receptor binding. J Bacteriol, 1992; 174:5923–5935.
8.
JonesCH, PinknerJS, RothR, HeuserJ, NicholesAV, AbrahamSNet al.FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci U S A, 1995; 92:2081–2085.
9.
HungC, BouckaertJ, HungDL, PinknerJ, WidbergC, DeFuscoAet al.Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Abstr Gen Meet Am Soc Microbiol, 2002; 102:41.
10.
HansonMS, BrintonCC. Identification and characterization of E. coli type-1 pilus tip adhesion protein. Nature, 1988; 332:265–268.
11.
ChoudhuryD, ThompsonA, StojanoffV, LangermannS, PinknerJ, HultgrenSJet al.X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science, 1999; 285:1061–1066.
12.
XieB, ZhouG, ChanSY, ShapiroE, KongXP, WuXRet al.Distinct glycan structures of uroplakins Ia and Ib - Structural basis for the selective binding of FimH adhesin to uroplakin Ia. J Biol Chem, 2006; 281:14644–14653.
13.
ZhouG, MoWJ, SebbelP, MinGW, NeubertTA, GlockshuberRet al.Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci, 2001; 114:4095–4103.
14.
WuXR, SunTT, MedinaJJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci U S A, 1996; 93:9630–9635.
15.
MulveyMA, Lopez-BoadoYS, WilsonCL, RothR, ParksWC, HeuserJet al.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science, 1998; 282:1494–1497.
16.
BouckaertJ, BerglundJ, SchembriM, De GenstE, CoolsL, WuhrerMet al.Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol, 2005; 55:441–455.
17.
ImbertyA, ChabreYM, RoyR. Glycomimetics and glycodendrimers as high affinity microbial anti-adhesins. Chemistry, 2008; 14:7490–7499.
18.
LindhorstTK, KieburgC, Krallmann-WenzelU. Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency. Glycoconj J, 1998; 15:605–613.
19.
DubberM, SperlingO, LindhorstTK. Oligomannoside mimetics by glycosylation of 'octopus glycosides' and their investigation as inhibitors of type 1 fimbriae-mediated adhesion of Escherichia coli. Org Biomol Chem, 2006; 4:3901–3912.
20.
SperlingO, FuchsA, LindhorstTK. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands. Org Biomol Chem, 2006; 4:3913–3922.
21.
HanZ, PinkerJS, FordB, ObermannR, NolanW, WildmanSA, HobbsD, EllenbergerT, CusumanoCK, HultgrenSJ, JanetkaJW. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem, 2010; 53:4779–4792.
22.
ErnstB, MagnaniJL. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov, 2009; 8:661–677.
23.
NagahoriN, LeeRT, NishimuraS, PageD, RoyR, LeeYC. Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands. Chembiochem, 2002; 3:836–844.
24.
AbgottsponD, RölliG, HoschL, SteinhuberA, JiangX, SchwardtO, CuttingB, SmieskoM, JenalU, ErnstB, TrampuzA. Development of an aggrgation assay to screen FimH antagoists. J Microbiol Methods, 2010; 82:249–255.
25.
FironN, OfekI, SharonN. Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium. Carbohydr Res, 1983; 120:235–249.
26.
FironN, AshkenaziS, MirelmanD, OfekI, SharonN. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun, 1987; 55:472–476.
27.
SokurenkoEV, CourtneyHS, OhmanDE, KlemmP, HastyDL. FimH family of type 1 fimbrial adhesins: functional heterogeneity due to minor sequence variations among fimH genes. J Bacteriol, 1994; 176:748–755.
28.
HartmannM, HorstAK, KlemmP, LindhorstTK. A kit for the investigation of live Escherichia coli cell adhesion to glycosylated surfaces. Chem Commun, 2010; 46:330–332.
29.
SchaefferAJ, AmundsenSK, SchmidtLN. Adherence of Escherichia coli to human urinary tract epithelial cells. Infect Immun, 1979; 24:753–759.
30.
HorstAK, KotterS, LindhorstTK, LudwigA, BrandtE, WagenerC. Binding inhibition of type 1 fimbriae to human granulocytes: a flow cytometric inhibition assay using trivalent cluster mannosides. Med Microbiol Immunol, 2001; 190:145–149.
31.
TouaibiaM, WellensA, ShiaoTC, WangQ, SiroisS, BouckaertJet al.Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH. ChemMedChem, 2007; 2:1190–1201.
32.
YakovenkoO, SharmaS, ForeroM, TchesnokovaV, AprikianP, KiddB, MachA, VogelV, SokurenkoE, ThomasWE. FimH forms catch bonds that are enhanced by mechanical force due to allosteric regulation. J Biol Chem, 2008; 283:11596–11605.
33.
AprikianP, TchesnokovaV, KiddB, YakovenkoO, Yarov-YarovoyV, TrinchinaEet al.Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose. J Biol Chem, 2007; 282:23437–23446.
34.
RabbaniS, JiangX, SchwardtO, ErnstB. Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay. Anal Biochem, 2010; 407:188–195.
35.
MulveyMA, SchillingJD, HultgrenSJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun, 2001; 69:4572–4579.
36.
OscarsonS, TidenAK. Syntheses of the octyl and tetradecyl glycosides of 3,6-di-o-alpha-deuteriummannopyranosyl-alpha-deuterium-mannopyranose and of 3,4-di-o-alpha-deuterium-mannopyranosyl-alpha-deuterium-mannopyranose a new way for 2,4-di-o-protection of mannopyranosides. Carbohydr Res, 1993; 247:323–328.
37.
KleinT, AbgottsponD, WittwerM, RabbaniS, HeroldJ, JiangX, KleebS, LüthiC, ScharenbergM, BezençonJ, GublerE, PangL, SmieskoM, SchwardtO, ErnstB. FimH Antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, 2010; 53:8627–8641.
38.
ElsinghorstEA. Measurement of invasion by gentamicin resistance. Methods Enzymol, 1994; 236:405–420.
39.
PilsS, SchmitterT, NeskeF, HauckCR. Quantification of bacterial invasion into adherent cells by flow cytomet ry. J Microbiol Methods, 2006; 65:301–310.
40.
BouckaertJ, MackenzieJ, de PazJL, ChipwazaB, ChoudhuryD, ZavialovAet al. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes. Mol Microbiol, 2006; 61:1556–1568.
